Eveotox injections for moderate to severe glabellar lines
Official title: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection (Eveotox) Compared With a Single Treatment of Botox and Placebo,and Repeated Treatment of Eveotox in Moderate to Severe Glabellar Lines
Run by JHM BioPharma (Tonghua) Co. , Ltd. · NCT06937944 · Data updated 2026-11-12
This trial tests whether Eveotox injections can reduce moderate to severe glabellar lines in adults aged 18–65 compared with Botox and a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 669 (estimated) |
| Sponsor | JHM BioPharma (Tonghua) Co. , Ltd. Research network |
| Locations | 15 sites (Beijing, Beijing Municipality and 14 other locations) |
| Status | Recruiting |
| Started | April 30, 2025 |
| Main results expected | February 9, 2026 |
| Study ends | September 2026 |
| Registry record updated | September 23, 2026 |
| Trial ID | NCT06937944 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 65 with moderate or severe glabellar lines at maximum frown who can attend scheduled visits and meet safety criteria are eligible to participate.
✕Probably not a fit
People with known hypersensitivity to botulinum toxin A, recent similar injections within six months, permanent glabellar implants or recent semi-permanent fillers, active injection-site infections, or disqualifying skin disease are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 3 program includes a randomized, double-blind, single-injection, active- and placebo-controlled Part 1 and an open-label Part 2 of repeated injections to measure efficacy, safety, and immunogenicity of Eveotox. Participants are compared against onabotulinumtoxinA (Botox) and placebo, with clinical ratings by investigators and patients of glabellar line severity. Key outcomes include wrinkle severity improvement, adverse events, and antibody formation against the drug. The trial is conducted at multiple tertiary hospitals in Beijing and enrolls adults with moderate to severe glabellar lines.
Why it matters
Potential benefit: If successful, Eveotox could provide an effective and safe botulinum toxin A option for reducing moderate to severe glabellar lines, potentially comparable to existing Botox treatments.
How similar studies have gone: OnabotulinumtoxinA (Botox) has a well-established record of success for glabellar lines, while recombinant formulations like Eveotox are newer and have limited phase 3 data published.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female subjects who are between 18 to 65 years of age * Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale * Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale * Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial Exclusion Criteria: * Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug * Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening * Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety * Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting -
Peking University First Hospital
Beijing, Beijing Municipality, China Recruiting -
Peking University Third Hospital
Beijing, Beijing Municipality, China Recruiting -
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China Recruiting -
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China Recruiting -
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Show 9 more locations
-
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China Recruiting -
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting -
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China Recruiting -
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China Recruiting -
Xianyang Hospital of Yan'an University
Xianyang, Shanxi, China Recruiting -
West China Hospital, Sichuan University
Chengdu, Sichuan, China Recruiting -
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China Recruiting -
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, China Recruiting -
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Danhua Lin
- Email: danhua.lin@jhm-biopharma.com
- Phone: 15811460241
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Corabotase for glabellar lines in adults
A single-dose injection of corabotase (IPN10200) or placebo will be tested in adults with moderate to severe wrinkle-like lines between the eyebrows to see if it improves the lines and remains safe.
-
Combination of two botulinum toxins for upper facial lines in adults
This study tests whether a single treatment that combines trenibotulinumtoxinE with onabotulinumtoxinA can improve moderate to severe upper facial lines in adults.
-
See if HU-045 works for moderate to severe glabellar lines
This study tests HU-045 against Xeomin® in adults with moderate to severe glabellar lines to see which treatment works better and is safe.
-
Head-to-Head Comparison of BoNT-A Treatments for Glabellar Lines
A multicenter, triple-blind study will test all FDA-approved Botulinum Neurotoxin Type A products to see which best reduces glabellar frown lines and lasts the longest.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.